Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Simon M. Laws is active.

Publication


Featured researches published by Simon M. Laws.


Journal of Neurochemistry | 2003

Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription

Simon M. Laws; Eugene Hone; Sam Gandy; Ralph N. Martins

Alzheimers disease (AD) is the most commonly diagnosed form of dementia in the elderly. Predominantly this disease is sporadic in nature with only a small percentage of patients exhibiting a familial trait. Early‐onset AD may be explained by single gene defects; however, most AD cases are late onset (> 65 years) and, although there is no known definite cause for this form of the disease, there are several known risk factors. Of these, the ε4 allele of the apolipoprotein E (apoE) gene (APOE) is a major risk factor. The ε4 allele of APOE is one of three (ɛ2 ɛ3 and ɛ4) common alleles generated by cysteine/arginine substitutions at two polymorphic sites. The possession of the ɛ4 allele is recognized as the most common identifiable genetic risk factor for late‐onset AD across most populations. Unlike the pathogenic mutations in the amyloid precursor or those in the presenilins, APOEɛ4 alleles increase the risk for AD but do not guarantee disease, even when present in homozygosity. In addition to the cysteine/arginine polymorphisms at the ɛ2/ɛ3/ɛ4 locus, polymorphisms within the proximal promoter of the APOE gene may lead to increased apoE levels by altering transcription of the APOE gene. Here we review the genetic and biochemical evidence supporting the hypothesis that regulation of apoE protein levels may contribute to the risk of AD, distinct from the well known polymorphisms at the ɛ2/ɛ3/ɛ4 locus.


PLOS ONE | 2013

The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes

Mathew J. Sharman; Seyyed Hani Moussavi Nik; Mengqi M. Chen; Daniel Ong; Linda K. Wijaya; Simon M. Laws; Kevin Taddei; Morgan Newman; Michael Lardelli; Ralph N. Martins; Giuseppe Verdile

We investigated the guinea pig, Cavia porcellus, as a model for Alzheimer’s disease (AD), both in terms of the conservation of genes involved in AD and the regulatory responses of these to a known AD risk factor - high cholesterol intake. Unlike rats and mice, guinea pigs possess an Aβ peptide sequence identical to human Aβ. Consistent with the commonality between cardiovascular and AD risk factors in humans, we saw that a high cholesterol diet leads to up-regulation of BACE1 (β-secretase) transcription and down-regulation of ADAM10 (α-secretase) transcription which should increase release of Aβ from APP. Significantly, guinea pigs possess isoforms of AD-related genes found in humans but not present in mice or rats. For example, we discovered that the truncated PS2V isoform of human PSEN2, that is found at raised levels in AD brains and that increases γ-secretase activity and Aβ synthesis, is not uniquely human or aberrant as previously believed. We show that PS2V formation is up-regulated by hypoxia and a high-cholesterol diet while, consistent with observations in humans, Aβ concentrations are raised in some brain regions but not others. Also like humans, but unlike mice, the guinea pig gene encoding tau, MAPT, encodes isoforms with both three and four microtubule binding domains, and cholesterol alters the ratio of these isoforms. We conclude that AD-related genes are highly conserved and more similar to human than the rat or mouse. Guinea pigs represent a superior rodent model for analysis of the impact of dietary factors such as cholesterol on the regulation of AD-related genes.


Molecular Psychiatry | 2010

Examination of the current top candidate genes for AD in a genome-wide association study.

T M Feulner; Simon M. Laws; P Friedrich; Stefan Wagenpfeil; Sebastian H. R. Wurst; C Riehle; Klaus A. Kuhn; Michael Krawczak; Stefan Schreiber; Susanna Nikolaus; Hans Förstl; Alexander Kurz; Matthias Riemenschneider

With the advent of technologies that allow simultaneous genotyping of thousands of single-nucleotide polymorphisms (SNPs) across the genome, the genetic contributions to complex diseases can be explored at an unprecedented detail. This study is among the first to apply the genome-wide association study (GWAS) approach to Alzheimer disease (AD). We present our GWAS results from the German population for genes included in the ‘Top Results’ list on the AlzGene database website. In addition to the apolipoprotein E locus, we identified nominally significant association signals in six of the ten genes investigated, albeit predominantly for SNPs other than those already published as being disease associated. Further, all of the four AD genes previously identified through GWAS also showed nominally significant association signals in our data. The results of our comparative study reinforce the necessity for replication and validation, not only of GWAS but also of candidate gene case–control studies, in different populations. Furthermore, cross-platform comparison of genotyping results can also identify new association signals. Finally, our data confirm that GWAS, regardless of the platform, are valuable for the identification of genetic variants associated with AD.


Frontiers in Aging Neuroscience | 2015

Bone mineral density, adiposity, and cognitive functions

Hamid R. Sohrabi; Kristyn A. Bates; Michael Weinborn; Romola S. Bucks; Stephanie R. Rainey-Smith; Mark Rodrigues; Sabine M. Bird; Belinda M. Brown; John Beilby; Matthew Howard; Arthur Criddle; Megan Wraith; Kevin Taddei; Georgia Martins; Athena Paton; Tejal Shah; Satvinder S. Dhaliwal; Pankaj D. Mehta; Jonathan K. Foster; Ian James Martins; Nicola T. Lautenschlager; F.L. Mastaglia; Simon M. Laws; Ralph N. Martins

Cognitive decline and dementia due to Alzheimers disease (AD) have been associated with genetic, lifestyle, and environmental factors. A number of potentially modifiable risk factors should be taken into account when preventive or ameliorative interventions targeting dementia and its preclinical stages are investigated. Bone mineral density (BMD) and body composition are two such potentially modifiable risk factors, and their association with cognitive decline was investigated in this study. 164 participants, aged 34–87 years old (62.78 ± 9.27), were recruited for this longitudinal study and underwent cognitive and clinical examinations at baseline and after 3 years. Blood samples were collected for apolipoprotein E (APOE) genotyping and dual energy x-ray absorptiometry (DXA) was conducted at the same day as cognitive assessment. Using hierarchical regression analysis, we found that BMD and lean body mass, as measured using DXA were significant predictors of episodic memory. Age, gender, APOE status, and premorbid IQ were controlled for. Specifically, the List A learning from California Verbal Learning Test was significantly associated with BMD and lean mass both at baseline and at follow up assessment. Our findings indicate that there is a significant association between BMD and lean body mass and episodic verbal learning. While the involvement of modifiable lifestyle factors in human cognitive function has been examined in different studies, there is a need for further research to understand the potential underlying mechanisms.


Neurology | 2011

Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging.

Veer Gupta; Simon M. Laws; Victor L. Villemagne; David Ames; Ashley I. Bush; K. Ellis; James Lui; Colin L. Masters; Christopher C. Rowe; Cassandra Szoeke; Kevin Taddei; Ralph N. Martins

Objective: There is mounting evidence for the contribution of apoE to the pathophysiology of Alzheimer disease (AD). Studies also indicate that plasma apoE levels may reflect disease status, suggesting that apoE is a potential AD biomarker. However, while some studies of apoE levels in plasma have presented correlations with AD pathology, others have not. Thus, there is a lack of consensus as to the suitability of plasma apoE as an AD biomarker. The major objective of this cross-sectional study was to investigate total plasma apoE as well as levels of the apoE4 form in a large, highly characterized cohort which included both healthy controls and participants with early-stage AD. Methods: Total apoE and apoE4 were measured in 1,079 individuals drawn from the highly characterized Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Total and isoform-specific plasma apoE levels were then compared with cerebral Aβ load, as assessed by PET using Pittsburgh compound B (PiB). Results: Total apoE and apoE4 levels were found to be significantly lower in patients with AD in the entire cohort, and decrease with Aβ load in the PiB-PET subset. ApoE levels were significantly lower among ϵ4 homozygous individuals. In APOE ϵ3/ϵ4 heterozygote carriers, apoE4 levels decrease, indicating that apoE3 levels increase with disease. Conclusion: Analysis of cross-sectional data from the AIBL study indicates that plasma apoE levels are altered in AD and correlate with AD pathology level. The significance of these findings will be determined in the AIBL longitudinal study of aging.


Journal of Alzheimer's Disease | 2010

Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging

James Lui; Simon M. Laws; Qiao-Xin Li; Victor L. Villemagne; David Ames; Belinda M. Brown; Ashley I. Bush; Karl De Ruyck; Jasmin Dromey; K. Ellis; Noel G. Faux; Jonathan K. Foster; Chris Fowler; Veer Gupta; Peter J. Hudson; Katrina M. Laughton; Colin L. Masters; Kelly K. Pertile; Alan Rembach; Mira Rimajova; Mark Rodrigues; Christopher C. Rowe; Rebecca L. Rumble; Cassandra Szoeke; Kevin Taddei; Tania Taddei; Brett Trounson; Vanessa Ward; Ralph N. Martins

Amyloid-beta (Abeta) plays a central role in the pathogenesis of Alzheimers disease (AD) and has been postulated as a potential biomarker for AD. However, there is a lack of consensus as to its suitability as an AD biomarker. The objective of this study was to determine the significance of plasma Abeta as an AD biomarker and its relationship with Abeta load and to determine the effect of different assay methods on the interpretation of Abeta levels. Plasma Abeta1-40, Abeta1-42, and N-terminal cleaved fragments were measured using both a commercial multiplex assay and a well-documented ELISA in 1032 individuals drawn from the well-characterized Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Further, Abeta levels were compared to Abeta load derived from positron-emission tomography (PET) with the Pittsburgh compound B (PiB). Lower Abeta1-42 and Abeta1-42/1-40 ratio were observed in patients with AD and inversely correlated with PiB-PET derived Abeta load. However, assay methodology significantly impacted the interpretation of data. The cross-sectional analysis of plasma Abeta isoforms suggests that they may not be sufficient per se to diagnose AD. The value of their measurement in prognosis and monitoring of AD interventions needs further study, in addition to future longitudinal comparisons together with other predictors, which will determine whether plasma Abeta has diagnostic value in a panel of biomarkers.


Molecular Psychiatry | 2013

Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing

Belinda M. Brown; Jeremiah J. Peiffer; Kevin Taddei; James Lui; Simon M. Laws; Veer Gupta; Tania Taddei; Vanessa Ward; Mark Rodrigues; Samantha Burnham; Stephanie R. Rainey-Smith; Victor L. Villemagne; Ashley I. Bush; K. Ellis; Colin L. Masters; David Ames; S L Macaulay; Cassandra Szoeke; Christopher C. Rowe; Ralph N. Martins

Previous studies suggest physical activity improves cognition and lowers Alzheimers disease (AD) risk. However, key AD pathogenic factors that are thought to be influenced by physical activity, particularly plasma amyloid-β (Aβ) and Aβ brain load, have yet to be thoroughly investigated. The objective of this study was to determine if plasma Aβ and amyloid brain deposition are associated with physical activity levels, and whether these associations differed between carriers and non-carriers of the apolipoprotein E (APOE) ɛ4 allele. Five-hundred and forty six cognitively intact participants (aged 60–95 years) from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) were included in these analyses. Habitual physical activity levels were measured using the International Physical Activity Questionnaire (IPAQ). Serum insulin, glucose, cholesterol and plasma Aβ levels were measured in fasting blood samples. A subgroup (n=116) underwent 11C-Pittsburgh compound B (PiB) positron emission tomography (PET) scanning to quantify brain amyloid load. Higher levels of physical activity were associated with higher high density lipoprotein (HDL) (P=0.037), and lower insulin (P<0.001), triglycerides (P=0.019) and Aβ1−42/1−40 ratio (P=0.001). After stratification of the cohort based on APOE ɛ4 allele carriage, it was evident that only non-carriers received the benefit of reduced plasma Aβ from physical activity. Conversely, lower levels of PiB SUVR (standardised uptake value ratio) were observed in higher exercising APOE ɛ4 carriers. Lower plasma Aβ1−42/1−40 and brain amyloid was observed in those reporting higher levels of physical activity, consistent with the hypothesis that physical activity may be involved in the modulation of pathogenic changes associated with AD.


Neuroreport | 1999

The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease.

Simon M. Laws; Kevin Taddei; Georgia Martins; Athena Paton; Christopher Fisher; Roger Clarnette; Joachim Hallmayer; William S. Brooks; Samuel E. Gandy; Ralph N. Martins

Recent evidence suggests that a polymorphism in the regulatory region of the apolipoprotein E gene (APOE) is associated with an increased risk for developing Alzheimers disease (AD) independent of that conveyed by the epsilon4 allele of APOE. Previous work by our group indicated that plasma apolipoprotein E (apoE) levels were elevated in AD, raising the possibility that the -491 genotype might modify AD risk by increasing expression of the APOE gene. In a total of 638 individuals the -491AA genotype was significantly associated with AD (P < 0.005) while the TT genotype was associated with controls (P < 0.005). In 138 individuals the AA genotype showed significantly higher plasma apoE levels, independent of epsilon4 and AD status (P < 0.01) as well as within control and AD groups (P < 0.05). Within the AD group the AA genotype showed increased apoE levels when compared to AA controls (P < 0.0001). These results suggest that the -491 AA genotype is associated with increased plasma apoE levels, providing a potential basis for elucidating how that genotype increases the risk for developing AD.


Alzheimers & Dementia | 2014

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

Alan Rembach; Noel G. Faux; Andrew D. Watt; Kelly K. Pertile; Rebecca L. Rumble; Brett Trounson; Christopher Fowler; Blaine R. Roberts; Keyla Perez; Qiao-Xin Li; Simon M. Laws; Kevin Taddei; Stephanie R. Rainey-Smith; Joanne S. Robertson; Manu Vandijck; Hugo Vanderstichele; Kevin J. Barnham; K. Ellis; Cassandra Szoeke; S. Lance Macaulay; Christopher C. Rowe; Victor L. Villemagne; David Ames; Ralph N. Martins; Ashley I. Bush; Colin L. Masters

A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimers disease (AD).


Neurobiology of Aging | 2013

BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease

Yen Ying Lim; Victor L. Villemagne; Simon M. Laws; David Ames; Robert H. Pietrzak; K. Ellis; Karra D. Harrington; Pierrick Bourgeat; Olivier Salvado; David Darby; Peter J. Snyder; Ashley I. Bush; Ralph N. Martins; Colin L. Masters; Christopher C. Rowe; Pradeep J. Nathan; Paul Maruff

Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has previously been implicated in Alzheimers disease (AD)-related cognitive impairment. We aimed to determine the relationship between BDNF Val66Met and beta-amyloid (Aβ) on cognitive decline, hippocampal atrophy, and Aβ accumulation over 36 months in 165 healthy adults enrolled in the Australian Imaging, Biomarkers and Lifestyle study. In healthy adults with high Aβ, Met carriers showed significant and moderate-to-large declines in episodic memory, executive function, and language, and greater hippocampal atrophy over 36 months, compared with Val/Val homozygotes. BDNF Val66Met was not found to be related to rates of change in cognition or hippocampal volume in healthy adults with low Aβ. BDNF Val66Met did not relate to the amount of Aβ or to the rate of Aβ accumulation in either group. High Aβ levels coupled with Met carriage may be useful prognostic markers of accelerated cognitive decline and hippocampal degeneration in individuals in the preclinical stage of AD.

Collaboration


Dive into the Simon M. Laws's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Ames

Mental Health Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Maruff

Florey Institute of Neuroscience and Mental Health

View shared research outputs
Top Co-Authors

Avatar

K. Ellis

University of Melbourne

View shared research outputs
Top Co-Authors

Avatar

Olivier Salvado

Commonwealth Scientific and Industrial Research Organisation

View shared research outputs
Researchain Logo
Decentralizing Knowledge